Central nervous system targeted pharmaceutical compositions
The integrin-targeted exosome vector addresses the challenge of targeting the central nervous system by binding to brain-damaged cells and crossing the blood-brain barrier, enhancing therapeutic delivery and neuronal repair in brain and spinal cord injuries.
KR1020260112919APending Publication Date: 2026-07-21CHINA MEDICAL UNIVERSITY(TW)
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- CHINA MEDICAL UNIVERSITY(TW)
- Filing Date
- 2026-01-08
- Publication Date
- 2026-07-21
AI Technical Summary
Technical Problem
Current drug delivery technologies struggle to specifically bind to the central nervous system and penetrate the blood-brain barrier, limiting their effectiveness in treating brain and spinal cord damage diseases.
Method used
Development of an integrin-targeted exosome (ITExo vector) with an integrin antibody bound to its surface, which is genetically engineered to enhance binding to brain-damaged nerve cells and cross the blood-brain barrier, encapsulating miRNA-BDNF for therapeutic delivery.
Benefits of technology
The ITExo vector effectively reduces inflammatory factors and enhances regenerative factor expression, improving motor function and neuronal repair in animal models of brain and spinal cord injuries by delivering BDNF across the blood-brain barrier.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PAT00001_ABST
Abstract
The present invention provides a central nervous system targeted pharmaceutical composition that can be used to treat various forms of brain damage, wherein an integrin antibody is attached to a transmembrane protein of an exosome through genetic engineering, and said exosome is used as a carrier to encapsulate a therapeutic drug.
Need to check novelty before this filing date? Find Prior Art